Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PolyPid Ltd. (PYPD : NSDQ)

• Company Description    PolyPid Ltd. is a pharmaceutical company. It discovers, develops and commercializes antibiotic drugs for the prevention of surgical infections. The company's product candidate includes D-PLEX100, BONYPID-1000 and BONYPID-500 which are in clinical stage. PolyPid Ltd. is based in Petach Tikva, Israel. Number of Employees: 61

• Price / Volume Information    Yesterday's Closing Price: $3.38 Daily Weekly Monthly 20 Day Moving Average: 192,878 shares Shares Outstanding: 10.19 (millions) Market Capitalization: $34.45 (millions) Beta: 1.32 52 Week High: $4.42 52 Week Low: $2.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.46% -4.83% 12 Week 23.36% 4.10% Year To Date 11.18% 6.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18 HASIVIM STREET - PETACH TIKVA,L3 495376 ISR ph: 972-74-719-5700 fax: - ir@polypid.com http://www.polypid.com

• General Corporate Information    Officers Dikla Czaczkes Akselbrad - Chief Executive Officer Jacob Harel - Chairman Ori Warshavsky - Chief Operating Officer Jonny Missulawin - Chief Financial Officer Yechezkel Barenholz - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M8001Q126 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 10.19 Most Recent Split Date: 9.00 (0.03:1) Beta: 1.32 Market Capitalization: $34.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 400.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 48.91% vs. Previous Quarter: 38.05% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -1,069.37 12/31/24 - -624.10 ROA 06/30/25 - - 03/31/25 - -151.85 12/31/24 - -129.28 Current Ratio 06/30/25 - - 03/31/25 - 0.71 12/31/24 - 1.31 Quick Ratio 06/30/25 - - 03/31/25 - 0.71 12/31/24 - 1.31 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.75 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 4.43 12/31/24 - 0.08 Debt-to-Capital 06/30/25 - - 03/31/25 - 81.58 12/31/24 - 7.62

Powered by Zacks Investment Research ©